AtCor Medical claimed that its SphygmoCor system visibly identifies the effects of reflected blood pressure in the central aortic pressure wave, effects which cannot be detected with standard blood pressure monitoring.

Duncan Ross, CEO of AtCor Medical, said: “AtCor has closed new contracts valued at $2.9m since March, demonstrating the resurgence of the pharmaceutical trial sector since US healthcare reform legislation was signed.

“This significant contract confirms AtCor’s market position as the leading provider of noninvasive central blood pressure and arterial stiffness measurement in clinical trials. It also shows AtCor’s reputation for high levels of customer satisfaction is being rewarded through expanded business with long-term clients.

“Scientific publications continue to reinforce the importance of using central blood pressure as a measurement. This mounting body of evidence helps to drive our sales to pharmaceutical businesses and supports accelerated adoption of SphygmoCor in clinical practice. Understanding a drug’s effect on central pressure is vitally important in assessing efficacy and in assuring drug safety. It is equally important in patient care.”

AtCor Medical develops and markets products for the early detection of cardiovascular risk and management of cardiovascular disease.